Oxidative stress, trace elements, and circulating microparticles in patients with Gaucher disease before and after enzyme replacement therapy

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 1, 2015, Pages 58-65

  Zahran, Asmaa M ^a   Elsayh, Khalid I ^b   El Deek, Sahar E M ^b   El Baz, Mona A H ^b  

^a ASSIUT UNIVERSITY   (Egypt)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

flow cytometry; Gaucher disease; microparticles

Indexed keywords

CHITOTRIOSIDASE; COPPER; HEMOGLOBIN; LIPID PEROXIDE; NITRIC OXIDE; SELENIUM; ZINC; BETA N ACETYLHEXOSAMINIDASE; GLUCOSYLCERAMIDASE; TRACE ELEMENT;

AGE; ARTICLE; AVASCULAR NECROSIS; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; ENZYME REPLACEMENT; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; GAUCHER DISEASE; GENDER; GRANULOCYTE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KYPHOSCOLIOSIS; LEUKOCYTE; LIPID BLOOD LEVEL; LIVER SIZE; MALE; MEMBRANE MICROPARTICLE; MONOCYTE; OXIDATIVE STRESS; SELENIUM BLOOD LEVEL; SKELETON MALFORMATION; SPLEEN SIZE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; ZINC BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; PRESCHOOL CHILD;

CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; CHILD; CHILD, PRESCHOOL; COPPER; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEXOSAMINIDASES; HUMANS; LIPID PEROXIDES; MALE; NITRIC OXIDE; OXIDATIVE STRESS; SELENIUM; TRACE ELEMENTS; ZINC;

EID: 84914164220     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613489595     Document Type: Article

References (52)

1. Beutler E, Grabowsky GA The Metabolic and Molecular Basis of Inherited Diseases. Scriver CR Beaudet AL Sly WS Valle D, ed. New York, NY: McGraw-Hill ; 2001: 3635-3668.
2. Deganuto M, Pittis MG, Pines A, et al. Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol. 2007 ; 212 (1). 223-235
3. Enderlin C, Vogel R, Conaway P. Gaucher disease. Am J Nurs. 2003 ; 103 (12). 50-60
4. Beutler E. Gaucher disease. Arch Intern Med. 1999 ; 159 (8). 881
5. Mehta A. Epidemiology and natural history of Gaucher's disease. Eur J Intern Med. 2006 ; 17 (suppl). S2 - S5
6. Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci. 2004 ; 25 (3). 147-151
7. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu Rev Genomics Hum Genet. 2003 ; 4: 403-436
8. Cesar GF. Relevance, essentiality and toxicity of trace elements in human health. Mol Aspects Med. 2005 ; 26 (4-5). 235-244
9. Kalkan Ucar S, Coker M, Sözmen E, Goksen Simsek D, Darcan S.. An association among iron, copper, zinc, and selenium, and antioxidative status in dyslipidemic pediatric patients with glycogen storage disease types IA and III. J Trace Elem Med Biol. 2010 ; 24 (1). 42-45
10. Connell R, Young VM, Toborek M, et al. Zinc attenuates tumor necrosis factor-mediated activation of transcription factors in endothelial cells. J Am Coll Nutr. 1997 ; 16 (5). 411-417
11. Freyssinet JM. Cellular microparticles: what are they bad or good for?. J Thromb Haemost. 2003 ; 1 (7). 1655-1662
12. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction (review). Front Biosci. 2004 ; 9: 1118-1135
13. Boulanger CM, Tedgui A. Dying for attention: microparticles and angiogenesis. Cardiovasc Res. 2005 ; 67 (1). 1-3
14. Beyer C, Pisetsky DS.. The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol. 2010 ; 6 (1). 21-29
15. Fontana V, Jy W, Ahn ER, et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thrombo Res. 2008 ; 122 (5). 599-603
16. Wang JM, Hung YJ, Wang Y, et al. Increased circulating CD31+/CD42- microparticles are associated with impaired systemic artery elasticity in healthy subjects. Am J Hypertens. 2007 ; 20 (9). 957-964
17. Helal O, Defoort C, Robert S, et al. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis. 2011 ; 21 (9). 665-671
18. Mignot C, Doummar D, Maire I, de Villemeur TB. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006 ; 28 (1). 39-48
19. Buege JA, Aust SD. Microsomal lipid peroxidation, modified by adding the BHT solution to prevent further lipid peroxidation during boiling. Methods Enzymol. 1978 ; 52: 302-310
20. Van Bezooijen RL, Que I, Ederveen AG, Kloosterboer HJ, Popapoulos SE, Lowik CW. Plasma nitrate + nitrite level are regulated by ovarian steroids but do not correlated with trabecular bone mineral density in rats. J Endocrinol. 1998 ; 159 (1). 27-34
21. van Beers JE, Schaap CLM, Berckmans JR, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009 ; 94 (11). 1513-1519
22. Sommeijer DW, Joop K, Leyte A, Reitsma PH, ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost. 2005 ; 3 (6). 1168-1171
23. Trappenburg CM, van Schilfgaarde M, Marchetti M, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica. 2009 ; 94 (7). 911-918
24. Bahr BA, Bendiske J. The neuropathogenic contributions of lysosomal dysfunction. J Neurochem. 2002 ; 83 (3). 481-489
25. Roversi FM, Galdieri LC, Grego BH, et al. Blood oxidative stress markers in Gaucher disease patients. Clin Chim Acta. 2006 ; 364 (1-2). 316-320
26. Hong YB, Kim EY, Jung SJ. Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse. J Korean Med Sci. 2006 ; 21 (4). 733-738
27. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem. 1982 ; 39 (3). 709-718
28. Hannun YA, Bell RM. Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science. 1987 ; 235 (4789). 670-674
29. Giri S, Jatana M, Rattan R, Won JS, Singh I, Singh AK. Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. FASEB J. 2002 ; 16 (7). 661-172
30. Kenneth JS, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999 ; 9 (1). 69-92
31. Torreilles F, Salman-Tabcheh S, Guerin M, Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Rev. 1999 ; 30 (2). 153-163
32. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmalcol. 2003 ; 54 (4). 469-487
33. Faber JL. Mechanisms of cell injury by activated oxygen species. Environ Health Perspect. 1994 ; 102 (suppl 10). 17-24
34. Wang T, Qin L, Liu B, et al. Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem. 2004 ; 88 (4). 939-947
35. Lal MA, Brismar H, Eklof AC, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int. 2002 ; 61 (6). 2006-2014
36. Rosenberger J, Petrovics G, Buzas B. Oxidative stress induces proorphanin FQ and proenkephalin gene expression in astrocytes through p38- and ERK-MAP kinases and NF-kappaB. J Nerurochem. 2001 ; 79 (1). 35-44
37. Oteiza PI, Mackenzie GG, Verstraeten SV. Metals in neurodegeneration: involvement of oxidants and oxidant-sensitive transcription factors. Mol Aspects Med. 2004 ; 25 (1-2). 103-115
38. Zago MP, Oteiza PI. The antioxidant properties of zinc: interactions with iron and antioxidants. Free Radic Biol Med. 2001 ; 31 (2). 266-274
39. Percival SS.. Copper and immunity. Am J Clin Nut. 1998 ; 67 (suppl 5). 1064S - 1068S
40. Kanumakala S, Boneh A, Zacharin M. Pamidronate treatment improves bone mineral density in children with Menkes disease. J Inherit Metab Dis. 2002 ; 25 (5). 391-398
41. John L. Update on anemia and neutropenia in copper deficiency. Curr Opin Hematol. 2012 ; 19 (1). 58-60
42. Levander OA, Beck MA. Interacting nutritional and infectious etiologies of Keshan disease. Insights from coxsackie virus b-induced myocarditis in mice deficient in selenium or vitamin E. Biol Trace Elem Res. 1997 ; 56 (1). 5-21
43. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol. 2007 ; 66 (2-3). 159-165
44. Jmoudiak M, Futerman HA. Gaucher disease: pathological mechanisms and modern management. Br J Haematol. 2005 ; 129 (2). 178-188
45. Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett. 2002 ; 526 (1-3). 93-96
46. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003 ; 3: 23-35
47. Gratchev A, Guillot P, Hakiy N, et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol. 2001 ; 53 (4). 386-392
48. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res. 2009 ; 335 (1). 143-151
49. Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res. 2003 ; 42 (5). 423-438
50. Wenstrup JR, Roca-Espiau M, Weinreb Bembi B.. Skeletal aspects of Gaucher disease: a review. Br J Rad. 2002 ; 75 (suppl). A2 - A12
51. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine (Baltimore). 1985 ; 64 (5). 310-322
52. Pastores GM, Einhorn TA. Skeletal complications of Gaucher disease: pathophysiology, evaluation and treatment. Semin Hematol. 1995 ; 32 (suppl 1). 20-27